Article

High bone turnover of type I collagen depends on fetal growth.

Department of Pediatrics, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Bone (impact factor: 4.02). 02/2006; 38(2):249-56. DOI:10.1016/j.bone.2005.07.017 pp.249-56
Source: PubMed

ABSTRACT The bone metabolic processes of proliferation and differentiation in preterm and term newborns have yet to be fully elucidated. Seventy-four umbilical cord blood samples were collected from preterm and term newborns delivered at 27 to 42 gestational weeks (GWs). Carboxy-terminal propeptide of type I procollagen (PICP), pyridinoline cross-linked telopeptide domain of type I collagen (ICTP), alkaline phosphatase (ALP), and bone-specific alkaline phosphatase (BAP) were measured. Calcitonin (CT), estrogen (E2), intact parathyroid hormone, and insulin-like growth factor-I (IGF-I) were also examined in 20 or 23 randomly selected samples. We conducted cross-sectional regression analyses for bone metabolic markers, fetal growth markers including GWs, birth weight (BW), height (BH) and head circumference (HC), and bone related hormones. PICP and ICTP activities were very high, but decreased significantly with fetal growth based on GWs, BW, BH, and HC changes (GWs, BW, and BH to both PICP and ICTP, P < 0.0001; HC to ICTP, P < 0.0001; HC to PICP, P < 0.05), while BAP and ALP did not change significantly. E2 and CT both showed a significant positive correlation with Ca (P < 0.05), but neither hormone had any apparent correlation with PICP, ALP, BAP, or ICTP. These results suggest very active bone formation and resorption of type I collagen to be dependent on fetal growth and that fetal osteoblasts dominate the proliferation phase of development rather than the maturation phase. However, factors contributing to high bone turnover in the fetus remain to be elucidated.

0 0
 · 
0 Bookmarks
 · 
27 Views
  • Source
    Article: Levels of bone collagen markers in preterm infants: relation to antenatal glucocorticoid treatment.
    Eftichia Korakaki, Dimitrios Gourgiotis, Agisilaos Aligizakis, Antonia Manoura, Eleftheria Hatzidaki, Emmanuel Giahnakis, Antonios Marmarinos, Maria Kalmanti, Christina Giannakopoulou
    [show abstract] [hide abstract]
    ABSTRACT: Although the beneficial effects of antenatally administered glucocorticoids are well documented, data on the potential of adverse consequences are limited. The objective of this study was to determine the effects of antenatally administered glucocorticoids on biochemical markers of bone metabolism of 55 preterm infants with a gestational age of 24-34 weeks who were enrolled in the study. Neonates were divided into two groups according to antenatal exposure to corticosteroids. There were no significant differences between the groups in clinical characteristics and anthropometric variables. We studied blood levels of osteocalcin (OC), carboxy-terminal propeptide of type I procollagen (PICP), and carboxy-terminal telopeptide of type I collagen (ICTP) at the time of delivery, on postnatal day 10, and at 2 and 4 months of life. Comparing the groups, we found statistically significant reduction in PICP levels at birth in corticosteroid-exposed neonates (P < 0.05). The levels of bone markers increased progressively on the first days of life. There were no significant differences between groups in bone markers at 10 days or at 2 and 4 months of life. We found no significant difference for bone markers between groups of infants exposed to single or repeated maternal corticosteroid treatments. In summary, antenatal glucocorticoid treatments are suggested to have a negative impact on fetal bone formation as reflected by low PICP levels at birth. However, this negative effect on bone markers seems to be a temporary effect that subsides on the first days of life and afterward.
    Journal of Bone and Mineral Metabolism 01/2007; 25(3):172-8. · 2.27 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

23 randomly
 
42 gestational weeks
 
active bone formation
 
alkaline phosphatase
 
apparent correlation
 
bone metabolic markers
 
bone metabolic processes
 
bone turnover
 
bone-specific alkaline phosphatase
 
Carboxy-terminal propeptide
 
cross-sectional regression analyses
 
fetal growth
 
fetal growth markers
 
fetal osteoblasts
 
HC changes
 
head circumference
 
insulin-like growth factor-I
 
pyridinoline cross-linked telopeptide domain
 
significant positive correlation
 
umbilical cord blood samples
 

Kazutoshi Nakano